Annual report [Section 13 and 15(d), not S-K Item 405]

License Agreements - Additional Information (Detail)

v3.25.0.1
License Agreements - Additional Information (Detail) - USD ($)
 12 Months Ended 102 Months Ended
Jan. 22, 2018
May 14, 2015
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2024
Jul. 31, 2016
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Cash     $ 200,000   $ 200,000  
Loss on contingent consideration     621,000 $ 528,000    
University of Bristol [Member]            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Maximum amount payable under license agreement, tied to milestones           $ 3,200,000
Payments under license agreement         125,000  
University of Bristol [Member] | Amendment to the University of Bristol License Agreement [Member]            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Maximum amount payable under license agreement, tied to milestones $ 1,700,000          
Payments under license agreement $ 37,500          
Sopharma [Member] | Share Purchase Agreement [Member]            
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]            
Percentage of outstanding shares acquired   75.00%        
Cash   $ 2,000,000        
Deferred payment   $ 2,000,000        
Fair value of the contingent consideration     1,100,000   $ 1,100,000  
Loss on contingent consideration     $ 600,000 $ 500,000